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The reliability of experimental findings depends on the rigour of experimental design. Here
we show limited reporting of measures to reduce the risk of bias in a random sample of life
sciences publications, significantly lower reporting of randomisation in work published in
journals of high impact, and very limited reporting of measures to reduce the risk of bias in
publications from leading United Kingdom institutions. Ascertainment of differences
between institutions might serve both as a measure of research quality and as a tool for
institutional efforts to improve research quality.
Bias occurs in in vivo research when there is a systematic error, or deviation from the truth, in
the results of a study or the conclusions drawn from it. There are a large number of potential
sources of bias, and the risks of some of the most important of these (selection bias and mea-
surement bias) may be mitigated through simple study design features (randomisation and
blinded assessment of outcome) [1,2]. Where risks of bias have been measured in systematic
reviews of in vivo studies, a low prevalence of reporting of such measures has been found, and
it is usual to find the largest reported efficacy in those studies meeting the lowest number of
checklist items [3–7]. Improving the conduct and reporting of in vivo research is a stated prior-
ity for many funders and publishers [8–10].
Measuring the impact of scientific work is important for research funders, journals, institu-
tions, and, not least, for researchers themselves. These measures are usually based on journal
impact factor or citation counts and are used to inform individual and institutional funding
decisions and academic promotions and to establish an informal hierarchy of journals that in
turn guides where authors choose to submit their work. A journal’s impact factor is derived
from the number of citations to articles published in that journal during the preceding 2 years
and as such reflects the extent to which publications in that journal have influenced other
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work. The use of journal impact factors for the purposes described above rests on an implied
assumption that highly cited articles, and by extension journals with a high impact factor,
describe high-quality research.
Previous research has identified a low prevalence of reporting of measures to reduce the risk
of bias for specific animal disease models [6,7,11–14], with studies thus identified as being at
risk of bias tending to give higher estimates of treatment effects [3,4]. Kilkenny and colleagues
showed that research in the United States and UK that was funded by public institutions
(National Institutes of Health [NIH], Medical Research Council [MRC], Wellcome) had a low
prevalence of reporting of measures to reduce the risk of bias [15], and Baker et al. showed
that, even after the endorsement of the Animal Research: Reporting of In Vivo Experiments
(ARRIVE) guidelines, reporting in PLOS journals (which have been one of the most enthusias-
tic proponents of the ARRIVE guidelines) remains low [16]. We have reported low prevalence
of measures to reduce the risk of bias in a random sample of laboratory biomedical research
[17]. However, since most previous studies have focused on the neurosciences, the reporting of
measures to reduce the risk of bias across in vivo research as a whole is not known.
In the UK, the Research Excellence Framework (REF; www.ref.ac.uk) assesses the quality of
research in higher education institutions. This is done with the stated purposes of (1) providing
guidance for funding bodies to inform the selective allocation of research funding, (2) account-
ability for public investment, and (3) benchmarking information. What makes for high quality
or excellence in research has to date been considered a combination of journal impact factor
alongside qualitative judgement. For the 2014 REF, quality is considered to be a function of
originality, significance, and rigour, with an intention to measure these against “international
research quality standards”—although these standards have not been defined. While the REF
guidelines were clear that assessments would not be based on journal impact factor, the num-
ber of citations to an article was admissible, and while they took quality to be “scientific rigour
and excellence, with regard to design, method, execution and analysis,” it is not clear whether,
and how, this was measured. Against this, many in UK science have felt that, as with previous
research assessment exercises, journal impact factor was the dominant consideration when
institutions decided which work, and which scientists, should be submitted to the 2014 round
(http://www.guardian.co.uk/science/occams-corner/2012/nov/30/1).
It is plausible that journal impact factor may reflect originality and significance, but these
dimensions are difficult to measure. Rigour, defined here as the use of experimental designs
that reduce the risk of bias, can be estimated by determining whether manuscripts report the
use of such measures. While the optimal design of each experiment may be specific to the
hypothesis being tested, there are, for in vivo experiments at least, some widely applicable
approaches that reduce the risk of bias.
These approaches include random allocation of animals to an experimental group (to
reduce confounding), blinded assessment of outcome measures (to reduce detection bias), a
statement of sample size calculation (to provide reassurance that studies were adequately pow-
ered and that repeated testing of accumulating data was not performed), and reporting of ani-
mals excluded from the analysis (to guard against attrition bias and the ad hoc exclusion of
data). Investigator conflict of interest might increase or decrease the risk of bias [18–20], and a
statement of whether or not a conflict of interest exists may help the reader to judge whether
this may have occurred. Concerns that much in vivo research appears not to report such mea-
sures led to the development of standards for the conduct and reporting of in vivo research in
specific disease areas [21–24] and across disease areas [1,25].
Objective judgement of the rigour of published work relies, of necessity, on information
contained in that publication. It is entirely possible that work was conducted with the greatest
rigour, but without a clear description of how bias was reduced, the reader cannot make such a
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judgement. Further, the overstatement of effects in studies that do not report measures to
reduce the risk of bias suggests, firstly, that many do not take such measures and, secondly,
that the true impact of bias may be even greater than has been observed.
Large effect sizes or unexpectedly “interesting” findings might lead to publication in a jour-
nal of high impact, while in fact those observations were due to the play of chance, to poor
experimental design, or to selective reporting of statistically significant effects from a host of
outcomes that were measured [26]. For instance, for gene association studies in psychiatry,
Munafo et al. have shown that it is commonplace for the first (usually small and underpow-
ered) study of the effect of a particular gene on the risks of developing depression to show large
effects and to be published in a journal of high impact, with subsequent (larger, more challeng-
ing, and more time-consuming) studies showing much smaller effects yet being published in
journals of much lower impact [27].
To provide an overview of the reporting of measures to reduce the risk of bias, we generated
a random sample of 2,000 publications indexed in PubMED. Details of all methods used are
given in the supplementary material (S1 Text), and all datasets are available in the Dryad repos-
itory: http://dx.doi.org/10.5061/dryad.cs3t8 [28]. For these studies, we ascertained the report-
ing of randomisation where this would be appropriate, of the blinded assessment of outcome,
of a sample size calculation, and of whether the authors had a potential conflict of interest.
Excluding those not in English (339) or with subject matter related to chemistry or physics
(114) left 1,547 publications, of which 814 reported primary research. 149 of these (18%)
reported hypothesis testing experiments using live animals (S1 Fig), and full texts for all but
three of these were retrieved. Twenty-seven publications reported randomisation (out of 134 in
which this would have been appropriate; 20%). Four of 146 (3%) reported the blinded assess-
ment of outcome, 15 of 146 (10%) reported a conflict of interest statement, and none of the 146
reported a sample size calculation. Reporting of randomisation increased from 9% in the first
quintile of year of publication (1941–1978) to 33% in the last quintile (2008–2012), blinded
assessment of outcome from 0% to 7%, and conflict of interest reporting from 3% to 40% (Fig
1).
Next, we examined the reporting of measures to reduce the risk of bias in publications iden-
tified in a nonrandom sample of systematic reviews of in vivo studies. Since 2004, the Collabo-
rative Approach to Meta-Analysis and Review of Experimental Data from Animal Studies
(CAMARADES) has facilitated the conduct of systematic reviews and meta-analysis of data
from in vivo experiments. Studies follow a common protocol [29] and approach to analysis
[30]. Data from completed reviews, including the reporting of measures to reduce the risk of
bias, are stored using common data architecture. Because we were also interested in any associ-
ation between rigour and journal impact factor, we selected for this analysis those publications
for which we could retrieve a journal impact factor for the year of publication.
We extracted data for 2,671 publications reporting drug efficacy in the eight disease models
with highest representation in that dataset. Randomisation was reported in 662 publications
(24.8%), blinded assessment of outcome in 788 (29.5%), a sample size calculation in 20 (0.7%),
and a statement of potential conflict of interest in 308 (11.5%). There was substantial variation
between different disease models in the prevalence of reporting of measures to reduce the risk
of bias, being lowest for glioma and experimental autoimmune encephalomyelitis and highest
for myocardial infarction (Fig 2). Reporting of randomisation increased from 14.0% (6/43) in
1992 to 42.0% in 2011 (31/77) (p< 0.001), reporting of the blinded assessment of outcome
from 16.3% (7/43) to 39.0% (30/77) (p< 0.001), and reporting of a statement of possible con-
flict of interest from 2.3% (1/43) to 35.1% (27/77) (p< 0.001). The reporting of a sample size
calculation did not change (2.3% [1/43] in 1992 and 1.3% [1/77] in 2011) (Fig 3).
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Fig 1. (A) Prevalence of reporting of randomisation, blinded assessment of outcome, sample size
calculation, and conflict of interest in 146 publications describing in vivo research identified through
random sampling from PubMed; change in prevalence of (B) randomisation, (C) blinded assessment
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It is not known whether in vivo research published in high-impact journals is at lower risk
of bias than that published in journals of lower impact. If scientists could be confident that
their work would be judged on its own merits, then the case for expeditious publication in
well-indexed online journals with open access, unlimited space, and the lowest publication
costs would become unassailable. We therefore examined the relationship between journal
impact factor and reporting of risks of bias in these 2,671 publications.
of outcome, and (D) conflict of interest reporting in quintiles of year of publication. Vertical error bars
represent the 95% confidence intervals of the estimates (S1 Data).
doi:10.1371/journal.pbio.1002273.g001
Fig 2. Prevalence of reporting of (A) randomisation, (B) blinded assessment of outcome, (C) sample size calculations, and (D) conflict of interest
reporting in 2,671 publications describing the efficacy of interventions in animal models of Alzheimer’s disease (AD, n = 324 publications), focal
cerebral ischaemia (FCI, 704), glioma (175), Huntington’s disease (HD, 113), intracerebral haemorrhage (ICH, 72), experimental autoimmune
encephalomyelitis (EAE, 1029), myocardial infarction (MI, 69), and spinal cord injury (SCI, 185) identified in the context of systematic reviews.
Vertical error bars represent the 95% confidence intervals, and the horizontal grey bar represents the 95% confidence interval of the overall estimate (S2
Data).
doi:10.1371/journal.pbio.1002273.g002
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The median impact factor was 3.9 (interquartile range 2.6 to 6.3), and using median regres-
sion, there was no relationship between journal impact factor and the number of risk-of-bias
items reported (beta coefficient 0.14, 95% CI −0.02–0.31, r = 0.024, p> 0.05). However, there
were important differences in the reporting of individual risk-of-bias items. Median journal
impact factor was 2.6 higher for studies reporting a potential conflict of interest (95% CI 2.4–
2.9, r = 0.192, p< 0.001) but was 0.4 lower in studies reporting randomisation (95% CI 0.1–
0.6, r = 0.047, p = 0.001). There was no significant difference for either the blinded assessment
of outcome (−0.1, 95% CI −0.4–0.2, r = 0.056, p> 0.05) or sample size calculation (0.7, 95% CI
−0.8–2.1, r = 0.000, p> 0.05).
The prevalence of reporting of measures to reduce the risk of bias in each decile of journal
impact factor is shown in Fig 4. Only for a statement of a possible conflict of interest was
reporting highest in the highest decile of impact factor, perhaps reflecting the editorial policies
of such journals.
Fig 3. Change in prevalence of reporting of (A) randomisation, (B) blinded assessment of outcome, (C) sample size calculations, and (D) conflict of
interest reporting in quintiles of year of publication for 2,671 publications describing the efficacy of interventions in animal models of eight
different diseases identified in the context of systematic reviews. Vertical error bars represent the 95% confidence intervals of the estimates (S3 Data).
doi:10.1371/journal.pbio.1002273.g003
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We were also interested in whether the relationship between the reporting of measures to
reduce the risk of bias and journal impact factor had changed over time. For the reporting of
randomisation, there was such an interaction: in 1992 the median impact factor for studies
reporting randomisation was 0.3 higher than for studies not reporting randomisation, but by
Fig 4. Prevalence of reporting of (A) randomisation, (B) blinded assessment of outcome, (C) sample size calculations, and (D) conflict of interest
reporting by decile of journal impact factor in 2,671 publications describing the efficacy of interventions in animal models of eight different
diseases identified in the context of systematic reviews. Black lines indicate the median value in that decile, and grey lines indicate the 95% confidence
limits derived from nonparametric median regression (S4 Data).
doi:10.1371/journal.pbio.1002273.g004
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2011 this had reversed, with the median journal impact factor for studies reporting randomisa-
tion being 0.8 lower than that for studies not reporting randomisation.
Finally, we were interested to establish whether formal assessment of research performance
is sensitive to these issues of rigour. To do this, we measured the reporting of measures to
reduce the risk of bias in in vivo research published from the five UK institutions ranked high-
est across six units of assessment in biomedical sciences in the 2008 Research Assessment Exer-
cise (RAE) (www.rae.ac.uk). We identified 4,859 publications from these institutions with a
publication year of 2009 or 2010. By screening the title and abstract of these—and where neces-
sary, the full text—we identified 1,173 publications that contained primary reports of in vivo
research.
Alongside randomisation, blinding, and sample size estimation, Landis et al. [1] identified
transparency of data handling, including the a priori determination of rules for inclusion and
exclusion of subjects and data, as a core issue for study evaluation, For this analysis, we there-
fore assessed whether publications described such a priori determination, in place of ascertain-
ment of the reporting of a potential conflict of interest.
Overall, 148 publications reported randomisation, of 1,028 in which this would have been
appropriate (14.4%); 201 of 1,165 reported blinding (17.3%); 101 of 1,169 reported inclusion or
exclusion criteria or both (10.4%); and 16 of 1,168 reported a sample size calculation (1.4%).
Only one publication reported all four risk-of-bias measures [31], nine publications met three,
69 publications met two (7%), 297 publications met only one (32%), and 797 publications
(68%) did not report any of the measures to reduce the risk of bias.
Further, there were interesting differences between institutions. The reporting of randomi-
sation ranged from 7.2% (Institution B) to 16.3% (Institution A); the reporting of blinding
from 12.4% (A) to 23.6% (C), the reporting of inclusion and exclusion criteria from 4.6% (D)
to 11.6% (A), and the reporting of a sample size calculation from 0% (E) to 5.1% (D). There
were significant differences between institutions in the reporting of each risk-of-bias item; for
the reporting of randomisation, Institution B was significantly worse than all other institutions,
and for the reporting of a sample size calculation, Institution D was significantly better than all
other institutions (Fig 5). The rigour of research published from institutions judged more
harshly by the RAE is a matter of the greatest interest, particularly given the consequences of
such judgements on funding allocations.
These datasets were assembled at different times for different purposes, and so comparisons
between them have limited validity. However, it is possible to compare across the datasets the
reporting of measures to reduce the risks of bias in those publications with a publication year
of 2009 or 2010 (Table 1). Somewhat counter to expectations, reporting of randomisation was
lowest (17.3%, 201/1165) in the RAE dataset, higher (35.7%, 76/213) in the CAMARADES
dataset, and highest (50%, 7/14) in publications selected at random from PubMED.
There are of course a number of weaknesses to our approach. Foremost among these is that
our measures of rigour (the reporting of measures to reduce the risk of bias) and of perceived
quality (journal impact factor and RAE ranking) are of necessity very indirect: we were only
able to ascertain whether publications reported measures to reduce the risk of bias, not whether
they had actually done so. However, previous studies have shown that such reporting is associ-
ated with lower estimates of efficacy [3,4], and so it does appear that risk-of-bias reporting is,
at worse, a surrogate measure of true risk of bias. Further, the importance of reporting method-
ological approaches in sufficient detail to allow replication is well established. For perceived
study quality, the measures we used are relevant, being widely used to inform resource alloca-
tion decisions, including institutional funding and the promotion of individual scientists.
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Secondly, we have not been able to consider the consequences of any upward drift of journal
impact factor over time, although in the CAMARADES dataset, we observed only a small
increase in mean impact factor, from 4.28 in 1992 to 4.40 in 2011.
Thirdly, we had a low threshold for considering studies to meet the various criteria. Bara
et al. have shown [32] that for animal research carried in critical care journals, while some
mention of randomisation was present in 47 of 77 publications (61%), the method of randomi-
sation was described in only 1 (3%).
Finally, the relationship between institutional esteem and risk-of-bias reporting may be a
consequence of the editorial practices of the journals in which high-quality research is
reported; that is, they may be more likely to accept manuscripts from institutions of repute.
Alternatively, the relationship between journal impact factor and risk of bias may be a conse-
quence of such journals making publishing decisions based on institutional esteem rather than
the quality of submitted manuscripts. However, the most parsimonious explanation of our
findings is that journal editorial policies and those charged with assessing the quality of pub-
lished work, including peer reviewers, have given insufficient attention to experimental design
and the risk of bias, and that this has led investigators to believe that these factors are not as
important as the novelty of their findings.
In spite of these weaknesses, we believe we have provided important empirical evidence of
the reported rigour of biomedical research. Firstly, we show that reporting of measures to
reduce the risk of bias in certain fields of research has increased over time, but there is still
Fig 5. Prevalence of reporting of randomisation, blinded assessment of outcome, inclusion or
exclusion criteria, and sample size calculation in 1,173 publications describing in vivo research
published from five leading UK institutions (labelled A through E). For each institution, the vertical error
bars represent the 95% confidence intervals, and the horizontal grey bar represents the 95% confidence
interval of the overall estimate for that risk-of-bias item (S5 Data).
doi:10.1371/journal.pbio.1002273.g005
Table 1. Reporting of measures to reduce the risk of bias in publications from 2009–2010 that were
randomly selected, identified in the context of systematic reviews or from leading UK institutions.
Randomisation Blinding Sample Size Calculation
n/N % (95% CI) n/N % (95% CI) n/N % (95% CI)
PubMed 7/14 50 (23–77) 2/14 14 (2–43) 0/14 0 (0–23)
CAMARADES 76/213 36 (29–42) 79/213 37 (30–44) 2/213 1 (0–3)
Institutions 148/1028 14 (12–17) 201/1165 17 (15–20) 16/1168 1 (1–2)
doi:10.1371/journal.pbio.1002273.t001
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substantial room for improvement. Secondly, there appears to be little relationship between
journal impact factor and reporting of risks of bias, consistent with previous claims that impact
factor is a poor measure of research quality [33]. Thirdly, risk of bias was prevalent in a random
sample of publications describing in vivo research. Finally, we found that recent publications
from institutions identified in the UK 2008 RAE as producing research of the highest standards
were in fact at substantial risk of bias, with less than a third reporting even one of four measures
that might have improved the validity of their work. Further, there were significant differences
between institutions in the reporting of such measures.
It is sobering that of over 1,000 publications from leading UK institutions, over two-thirds
did not report even one of four items considered critical to reducing the risk of bias, and only
one publication reported all four measures. A number of leading journals have taken steps that
should over time improve the quality of the work they publish [8–10], and the effectiveness of
the various different measures that have been taken will become clear over time. Such measures
do not have to be expensive—Yordanov and colleagues have estimated [34] that half of 142
clinical trials at high risk of bias could be improved at low or no cost, and the same may well be
true for animal experiments.
Of greater concern is that there still appears to be a lack of engagement with these issues
amongst those charged with assessing the quality of published research. In the course of this
work, we approached the UK Higher Education Funding Council (HEFC) seeking details of
those publications submitted to them in the context of the 2014 REF; they declined a Freedom
of Information request on the basis that disclosure would not, in their view, be in the public
interest. The REF should of course have a role in championing good science, but it should also
be a force for improvement, seeking to provide measures against which institutions and scien-
tists can monitor improvements in the rigour of their research.
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